UK Study: Diabetes Technology Improves Quality of Life, Not Just Blood Sugar

A study from the UK, conducted by diabetes specialists at the University Hospitals of Derby and Burton NHS Foundation Trust, reveals that modern diabetes technologies are delivering benefits that go well beyond simply lowering blood glucose numbers. Published in Diabetes, Obesity & Metabolism (2024), this comprehensive review examined how devices like continuous glucose monitors (CGMs) and insulin pumps affect the everyday lived experience of people managing diabetes — what researchers call "patient-reported outcome measures," or PROMs.

What the UK Researchers Found

The research team, led by Liarakos, Crabtree, and Wilmot, reviewed existing studies on diabetes technology with a focus on outcomes that patients actually care about: quality of life, emotional well-being, treatment satisfaction, and diabetes-related distress. Their key findings include:

• CGM for Type 1 Diabetes (T1D): Continuous glucose monitoring appears to meaningfully improve quality of life in people with T1D. A major driver is the technology's ability to prevent or help manage hypoglycemia (dangerously low blood sugar, below 70 mg/dL by US standards). Fewer scary low blood sugar episodes means less fear, better sleep, and greater peace of mind.
• CGM for Type 2 Diabetes (T2D): CGM also shows promise for improving quality of life in people with T2D, particularly those using insulin therapy — a group that faces similar hypoglycemia risks as T1D patients.
• Insulin Pumps: Evidence points to positive quality-of-life improvements for people with T1D using insulin pumps, though research in T2D patients remains limited.
• Hybrid Closed-Loop Systems ("Artificial Pancreas"): These advanced systems, which automatically adjust insulin delivery based on real-time glucose readings, showed increased treatment satisfaction, improved quality of life, and reduced diabetes-related distress in T1D. Whether all systems provide equal benefit or some work better than others is still being studied.

Why This Matters for US Patients

In the United States, insurance coverage decisions and clinical guidelines from organizations like the American Diabetes Association (ADA) have historically centered on measurable numbers — primarily HbA1c levels and time-in-range glucose data. The ADA recommends a target HbA1c below 7% (53 mmol/mol) for most adults, and CGM time-in-range targets of over 70% between 70–180 mg/dL.

This UK review makes a compelling argument that these numbers, while important, tell only part of the story. A patient whose blood sugar is technically controlled but who lives in constant fear of hypoglycemia, experiences burnout, or feels burdened by their treatment is not truly thriving. The UK's National Health Service (NHS) faces similar pressures to justify technology costs — meaning this research was designed with real-world resource constraints in mind, making it directly relevant to the US insurance and Medicare coverage debates surrounding CGMs and insulin pumps.

For US patients advocating for coverage of these devices, this study provides powerful ammunition: the benefits are not just clinical, they are human.

The Bottom Line

UK researchers are calling for patient quality-of-life measures to be treated as primary — not secondary — goals in diabetes technology research and clinical practice. For American patients, this means asking your care team not just "Is my A1c good?" but "Is my treatment making my life better?"

Source: Liarakos, Crabtree, Wilmot. "Patient-reported outcomes in studies of diabetes technology: What matters." Diabetes, Obesity & Metabolism, 2024. PMID: 39215657. DOI: 10.1111/dom.15858